RU2016145968A - Улучшенные способы производства средств адоптивной клеточной терапии - Google Patents
Улучшенные способы производства средств адоптивной клеточной терапии Download PDFInfo
- Publication number
- RU2016145968A RU2016145968A RU2016145968A RU2016145968A RU2016145968A RU 2016145968 A RU2016145968 A RU 2016145968A RU 2016145968 A RU2016145968 A RU 2016145968A RU 2016145968 A RU2016145968 A RU 2016145968A RU 2016145968 A RU2016145968 A RU 2016145968A
- Authority
- RU
- Russia
- Prior art keywords
- cell population
- cells
- cell
- cultured
- population
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 15
- 238000011467 adoptive cell therapy Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 37
- 210000001744 T-lymphocyte Anatomy 0.000 claims 19
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 6
- 230000026683 transduction Effects 0.000 claims 6
- 238000010361 transduction Methods 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 239000001963 growth medium Substances 0.000 claims 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 238000005406 washing Methods 0.000 claims 5
- -1 α v β 6 -integrin Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000001556 precipitation Methods 0.000 claims 4
- 206010003445 Ascites Diseases 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims 3
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims 3
- 208000002151 Pleural effusion Diseases 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000004700 fetal blood Anatomy 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 210000001165 lymph node Anatomy 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 230000008054 signal transmission Effects 0.000 claims 3
- 210000000952 spleen Anatomy 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 210000001541 thymus gland Anatomy 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100035139 Folate receptor alpha Human genes 0.000 claims 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 108010058905 CD44v6 antigen Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 102000012804 EPCAM Human genes 0.000 claims 1
- 101150084967 EPCAM gene Proteins 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 229920001917 Ficoll Polymers 0.000 claims 1
- 108050001931 Folate receptor alpha Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102000010956 Glypican Human genes 0.000 claims 1
- 108050001154 Glypican Proteins 0.000 claims 1
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 108050007237 Glypican-3 Proteins 0.000 claims 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims 1
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 101150057140 TACSTD1 gene Proteins 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 102000046157 human CSF2 Human genes 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
Claims (72)
1. Способ производства терапевтического средства на основе Т-клеток, включающий:
a) получение популяции клеток, которая содержит Т-клетки и антиген-презентирующие клетки (APC);
b) культивирование популяции клеток в среде для культивирования клеток, содержащей i) один или более цитокинов, ii) антитело к CD3 или его CD3-связывающий фрагмент и iii) антитело к CD28 или его CD28-связывающий фрагмент, B7-1 или его CD28-связывающий фрагмент, или B7-2 или его CD28-связывающий фрагмент, при этом культивирование активирует и стимулирует Т-клетки;
c) трансдукцию популяции активированных клеток с помощью вирусного вектора и
d) культивирование популяции клеток в ростовой среде для клеток для размножения трансдуцированных Т-клеток;
с производством тем самым терапевтического средства на основе T-клеток.
2. Способ по п. 1, где:
(a) популяцию клеток получают из периферической крови, мононуклеарных клеток периферической крови, костного мозга, ткани лимфатического узла, пуповинной крови, ткани тимуса, ткани из очага инфекции, асцитов, плеврального выпота, ткани селезенки или опухолей;
(b) Т-клетки получают из периферической крови, мононуклеарных клеток периферической крови, костного мозга, ткани лимфатического узла, пуповинной крови, ткани тимуса, ткани из очага инфекции, асцитов, плеврального выпота, ткани селезенки, опухолей или линии T-клеток;
(с) APC получают из периферической крови, мононуклеарных клеток периферической крови, костного мозга, ткани лимфатического узла, пуповинной крови, ткани тимуса, ткани из очага инфекции, асцитов, плеврального выпота, ткани селезенки или опухолей; или
(d) популяция клеток содержит мононуклеарные клетки периферической крови (PBMC).
3. Способ по любому из пп. 1-2, где:
(a) сбор или получение популяции клеток включает лейкаферез;
(b) выделение популяции клеток включает осаждение;
(c) выделение популяции клеток включает осаждение, которое включает градиент FICOLL™ или PERCOLL™;
(d) выделение популяции клеток включает осаждение, которое выполняют с помощью полуавтоматической проточной центрифуги; или
(e) выделение популяции клеток включает осаждение, которое выполняют с помощью Cobe 2991 Cell Processor, Cell Saver 5+ или полуавтоматической проточной центрифуги Elutra.
4. Способ по любому из пп. 1-2, где способ дополнительно включает:
(a) промывку популяции клеток в буфере или среде для культивирования клеток;
(b) промывку популяции клеток в ростовой среде для T-клеток (TCGM), содержащей один или более цитокинов;
(c) промывку популяции клеток в ростовой среде для T-клеток (TCGM), содержащей один или более цитокинов, выбранных из группы, включающей: IL-2, IL7, IL-15, IL-9 и IL-21;
(d) промывку популяции клеток в ростовой среде для T-клеток (TCGM), содержащей IL-2; или
(e) промывку популяции клеток в ростовой среде для T-клеток (TCGM), содержащей 250 МЕ/мл IL-2.
5. Способ по п. 1, где:
(a) популяцию клеток культивируют с растворимым антителом к CD3 и растворимым антителом к CD28;
(b) популяцию клеток культивируют с растворимым антителом к CD3 при концентрации приблизительно 50 нг/мл и растворимым антителом к CD28; или
(c) популяцию клеток культивируют с растворимым антителом к CD3 и растворимым антителом к CD28 при концентрации приблизительно 50 нг/мл.
6. Способ по п. 1, где:
(a) популяцию клеток на стадии b) культивируют в течение от приблизительно 12 часов до приблизительно 48 часов перед трансдукцией;
(b) популяцию клеток на стадии b) трансдуцируют во время активации;
(c) популяцию клеток на стадии b) культивируют в течение от приблизительно 1 часа до приблизительно 12 часов перед трансдукцией;
(d) популяцию клеток на стадии b) культивируют в течение от приблизительно 16 часов до приблизительно 32 часов перед трансдукцией;
(e) популяцию клеток на стадии b) культивируют в течение по меньшей мере 18 часов перед трансдукцией;
(f) популяцию клеток на стадии b) культивируют в течение по меньшей мере 24 часов перед трансдукцией;
(g) популяцию клеток на стадии d) трансдуцируют с помощью ретровирусного вектора; или
(h) популяцию клеток на стадии d) трансдуцируют с помощью лентивирусного вектора.
7. Способ по п. 5 или 6, где для трансдукции 1 x 108 высеянных клеток применяют от приблизительно 1 x 109 TU до приблизительно 2 x 109 TU вирусного вектора.
8. Способ по любому из пп. 1, 2, 5, 6, где:
(a) вирусный вектор разводят до 20% объем/объем от общего объема культуры;
(b) вирусный вектор разводят до приблизительно 40% - приблизительно 50% объем/объем от общего объема культуры;
(c) популяцию клеток подвергают трансдукции в течение от приблизительно 18 до приблизительно 48 часов;
(d) популяцию клеток подвергают трансдукции в течение от приблизительно 18 до приблизительно 36 часов;
(e) популяцию клеток подвергают трансдукции в течение приблизительно 24 часов;
(f) вирусный вектор содержит полинуклеотид, кодирующий химерный антигенный рецептор.
9. Способ по п. 8, где CAR содержит
a) внеклеточный домен, который связывает антиген, выбранный из группы, включающей фолатный рецептор альфа, 5T4, αvβ6-интегрин, BCMA, B7-H3, B7-H6, CAIX, CD19, CD20, CD22, CD30, CD33, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD138, CD171, CEA, CSPG4, EGFR, семейство EGFR, в том числе ErbB2 (HER2), EGFRvIII, EGP2, EGP40, EPCAM, EphA2, EpCAM, FAP, фетальный AchR, FRα, GD2, GD3, 'глипикан-3 (GPC3), HLA-A1+MAGE1, HLA-A2+MAGE1, HLA-A3+MAGE1, HLA-A1+NY-ESO-1, HLA-A2+NY-ESO-1, HLA-A3+NY-ESO-1, IL-11Rα, IL-13Rα2, лямбда-цепь, Lewis-Y, каппа-цепь, мезотелин, Muc1, Muc16, NCAM, лиганды NKG2D, NY-ESO-1, PRAME, PSCA, PSMA, ROR1, SSX, сурвивин, TAG72, TEM и VEGFR2;
b) трансмембранный домен, полученный из полипептида, выбранного из группы, включающей CD8α; CD4, CD28, CD45, PD1 и CD152;
c) один или более внутриклеточных доменов передачи костимулирующего сигнала, выбранных из группы, включающей CD28, CD54 (ICAM), CD134 (OX40), CD137 (41BB), CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1) и CD278 (ICOS); и
d) домен передачи сигнала CD3ζ.
10. Способ по п. 9, где:
(a) внеклеточный домен содержит антитело или антиген-связывающий фрагмент, которые связывают антиген;
(b) трансмембранный домен получен из CD8α или CD28;
(c) один или более доменов передачи костимулирующего сигнала выбраны из группы, включающей CD28, CD134 и CD137;
(d) CAR дополнительно содержит полипептид шарнирной области;
(e) CAR дополнительно содержит полипептид шарнирной области IgG1 или CD8α;
(f) CAR дополнительно содержит сигнальный пептид; или
(g) CAR дополнительно содержит сигнальный полипептид тяжелой цепи IgG1, сигнальный полипептид CD8α или сигнальный полипептид альфа-субъединицы рецептора GM-CSF человека.
11. Способ по п. 1, где:
(a) популяцию клеток на стадии d) культивируют для размножения в течение от приблизительно 5 до приблизительно 8 дней;
(b) популяцию клеток на стадии d) культивируют для размножения в течение от приблизительно 5 дней до приблизительно 8 дней в пакете для культивирования клеток;
(c) популяцию клеток на стадии d) культивируют для размножения в течение приблизительно 5 дней в пакете для культивирования клеток, а затем культивируют в течение приблизительно 3 дней в биореакторе; или
(d) популяцию клеток на стадии d) культивируют для размножения в течение от приблизительно 5 дней до приблизительно 8 дней в биореакторе.
12. Способ по п. 11, где биореактор представляет собой биореактор WAVE или биореактор GREX.
13. Способ по п. 1, где:
(a) количество Т-клеток возрастает по меньшей мере в 50 раз в ходе культивирования на стадии d);
(b) количество Т-клеток возрастает по меньшей мере в 100 раз в ходе культивирования на стадии d);
(c) количество Т-клеток возрастает по меньшей мере в 300 раз в ходе культивирования на стадии d);
(d) количество Т-клеток возрастает по меньшей мере в 400 раз в ходе культивирования на стадии d);
(e) количество Т-клеток возрастает по меньшей мере в 500 раз в ходе культивирования на стадии d); или
(f) количество Т-клеток возрастает по меньшей мере в 600 раз в ходе культивирования на стадии d).
14. Композиция, содержащая произведенные Т-клетки по любому из пп. 1-13 и физиологически приемлемый наполнитель.
15. Способ лечения новообразования у субъекта, нуждающегося в этом, включающий введение субъекту терапевтического средства на основе T-клеток по п. 14.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984558P | 2014-04-25 | 2014-04-25 | |
US61/984,558 | 2014-04-25 | ||
PCT/US2015/027518 WO2015164745A1 (en) | 2014-04-25 | 2015-04-24 | Improved methods for manufacturing adoptive cell therapies |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016145968A true RU2016145968A (ru) | 2018-05-28 |
RU2016145968A3 RU2016145968A3 (ru) | 2018-11-13 |
RU2741899C2 RU2741899C2 (ru) | 2021-01-29 |
Family
ID=54333268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016145968A RU2741899C2 (ru) | 2014-04-25 | 2015-04-24 | Улучшенные способы производства средств адоптивной клеточной терапии |
Country Status (25)
Country | Link |
---|---|
US (1) | US20170051252A1 (ru) |
EP (2) | EP3738597A1 (ru) |
JP (4) | JP6817069B2 (ru) |
KR (3) | KR20160141865A (ru) |
CN (2) | CN106456670B (ru) |
AU (2) | AU2015249376C1 (ru) |
BR (1) | BR112016024957A2 (ru) |
CA (1) | CA2946552A1 (ru) |
CY (1) | CY1123142T1 (ru) |
DK (1) | DK3134095T3 (ru) |
ES (1) | ES2800906T3 (ru) |
HR (1) | HRP20200978T1 (ru) |
HU (1) | HUE049514T2 (ru) |
IL (2) | IL248349B (ru) |
LT (1) | LT3134095T (ru) |
MX (2) | MX370018B (ru) |
NZ (1) | NZ725201A (ru) |
PL (1) | PL3134095T3 (ru) |
PT (1) | PT3134095T (ru) |
RS (1) | RS60544B1 (ru) |
RU (1) | RU2741899C2 (ru) |
SG (2) | SG11201608744VA (ru) |
SI (1) | SI3134095T1 (ru) |
WO (1) | WO2015164745A1 (ru) |
ZA (2) | ZA201607175B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2810092C2 (ru) * | 2018-09-27 | 2023-12-21 | Отолус Лимитед | Химерный антигенный рецептор |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105264127B (zh) | 2013-03-15 | 2019-04-09 | Gpb科学有限责任公司 | 颗粒的片上微流体处理 |
US10324011B2 (en) | 2013-03-15 | 2019-06-18 | The Trustees Of Princeton University | Methods and devices for high throughput purification |
US20150064153A1 (en) | 2013-03-15 | 2015-03-05 | The Trustees Of Princeton University | High efficiency microfluidic purification of stem cells to improve transplants |
CN116656605A (zh) | 2014-04-16 | 2023-08-29 | 朱诺治疗有限公司 | 用于扩增细胞群的方法、试剂盒及装置 |
US11400115B2 (en) | 2014-04-23 | 2022-08-02 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
SG11201608754SA (en) | 2014-04-25 | 2016-11-29 | Bluebird Bio Inc | Mnd promoter chimeric antigen receptors |
BR112016028644B1 (pt) | 2014-06-06 | 2019-12-03 | Bluebird Bio Inc | Método in vitro ou ex vivo para fabricar células t, composição compreendendo um agente de crioproteção e uma população de células efetoras imunes e usos terapêuticos dadita composição |
ES2878449T3 (es) | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
AU2015360845B2 (en) | 2014-12-12 | 2020-11-26 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
EP3240803B1 (en) | 2014-12-29 | 2021-11-24 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
EP3283619B1 (en) | 2015-04-17 | 2023-04-05 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
FR3038324B1 (fr) | 2015-06-30 | 2020-10-30 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
EP3325504A1 (en) | 2015-07-21 | 2018-05-30 | Novartis AG | Methods for improving the efficacy and expansion of immune cells |
US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
TWI630934B (zh) * | 2015-10-14 | 2018-08-01 | 瑞典商神經毫微股份有限公司 | 移植醫藥設備到神經組織中的方法以及設備 |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
CA3002742A1 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
WO2017099712A1 (en) * | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
US20190269727A1 (en) * | 2015-12-28 | 2019-09-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
TW201736399A (zh) | 2015-12-31 | 2017-10-16 | 財團法人生物技術開發中心 | 抗vegfr抗體及其應用 |
BR112018014615A2 (pt) | 2016-01-20 | 2018-12-11 | The Scripps Research Institute | composições de anticorpo para ror1 e métodos relacionados |
US20190161530A1 (en) * | 2016-04-07 | 2019-05-30 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
EP3439685B1 (en) * | 2016-04-08 | 2023-07-05 | Emory University | Methods of treating cancer and infectious diseases using cell based therapies |
CN105907790A (zh) * | 2016-06-21 | 2016-08-31 | 林志国 | 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法 |
US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
EP3528630A4 (en) * | 2016-10-21 | 2020-05-13 | Georgia Tech Research Corporation | T-LYMPHOCYTE EXPANSION METHODS AND SYSTEMS |
WO2018080997A1 (en) * | 2016-10-24 | 2018-05-03 | Gpb Scientific, Llc | Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
CN110234756A (zh) * | 2017-01-18 | 2019-09-13 | F1肿瘤医学公司 | 转导和扩增免疫细胞的方法及其用途 |
EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
US11851659B2 (en) | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
JP2020511987A (ja) * | 2017-03-28 | 2020-04-23 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 移植された組織を拒絶反応から保護するための方法 |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
CN109134660B (zh) * | 2017-06-16 | 2022-07-01 | 上海恒润达生生物科技股份有限公司 | 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途 |
CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
EP3648757A4 (en) * | 2017-07-03 | 2020-11-25 | Development Center for Biotechnology | ANTI-VEGFR ANTIBODIES AND USES THEREOF |
SG11202000846WA (en) | 2017-08-07 | 2020-02-27 | Nbe Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
JP7275104B2 (ja) | 2017-08-09 | 2023-05-17 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 |
KR102296580B1 (ko) | 2017-09-01 | 2021-09-02 | 론자 워커스빌 아이엔씨. | 엔드-투-엔드 세포 요법의 자동화 |
EP3675876A4 (en) * | 2017-09-01 | 2021-06-02 | GPB Scientific, Inc. | PROCESSES FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS |
WO2019079569A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN |
CN107893055B (zh) * | 2017-11-03 | 2020-07-17 | 深圳市默赛尔生物医学科技发展有限公司 | 一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途 |
US20200330983A1 (en) * | 2017-11-10 | 2020-10-22 | Juno Therapeutics, Inc. | Closed-system cryogenic vessels |
CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
CA3088095A1 (en) | 2017-11-15 | 2019-05-23 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
JP2021509009A (ja) | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | Bcmaターゲティングキメラ抗原受容体及びその使用 |
SG11202005272SA (en) * | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
CN112125976B (zh) * | 2018-01-26 | 2022-06-03 | 重庆精准生物技术有限公司 | 改造的铰链及其在构建car骨架中的应用 |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
AU2019218093A1 (en) * | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
DE102018108996B4 (de) | 2018-02-09 | 2021-10-21 | Immatics US, Inc. | Verfahren zur Herstellung autologer T-Zellen |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
CN110272481A (zh) * | 2018-03-14 | 2019-09-24 | 中国科学院广州生物医药与健康研究院 | 识别mage1抗原短肽的t细胞受体 |
EP3765121A4 (en) * | 2018-03-14 | 2021-12-22 | Thermogenesis Corp. | ACTIVATION / TRANSDUCTION SYSTEMS AND PROCEDURES COMPATIBLE WITH BUILD-UP ACTIVATED CELL SORTING (BACS) |
DE102018108612A1 (de) * | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
SG11202010319RA (en) | 2018-04-27 | 2020-11-27 | Iovance Biotherapeutics Inc | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
CN112424342A (zh) * | 2018-05-08 | 2021-02-26 | 生命科技公司 | 用于培养和扩增细胞的组合物和方法 |
CN108929862A (zh) * | 2018-08-01 | 2018-12-04 | 上海市第人民医院 | 一种恶性肿瘤肺转移伴恶性胸腔积液的t细胞制备与扩增方法及其应用 |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
SG11202101825QA (en) | 2018-08-31 | 2021-03-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3876979A4 (en) | 2018-11-08 | 2022-08-24 | NexImmune, Inc. | COMPOSITIONS OF T LYMPHOCYTES WITH ENHANCED PHENOTYPIC PROPERTIES |
US20220017862A1 (en) * | 2018-11-16 | 2022-01-20 | Celgene Corporation | Improved t cell manufacturing process |
US20220033848A1 (en) * | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
KR20210107749A (ko) | 2018-12-21 | 2021-09-01 | 옥테인 바이오테크 인코포레이티드 | 모듈식 생물학적 생산 유닛들을 위한 캐러셀 |
CN113195725A (zh) | 2018-12-21 | 2021-07-30 | 隆萨沃克斯维尔股份有限公司 | 病毒载体的自动化生产 |
US11773365B2 (en) | 2019-02-08 | 2023-10-03 | Lonza Walkersville, Inc. | Cell concentration methods and devices for use in automated bioreactors |
US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
WO2020191172A1 (en) * | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
CA3135852A1 (en) * | 2019-04-03 | 2020-10-08 | Akron Biotechnology, Llc | Cryopreservation and cell culture media |
AU2020254699A1 (en) * | 2019-04-05 | 2021-12-02 | 2Seventy Bio, Inc. | Manufacturing anti-BCMA CAR T cells |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
EP4021180A4 (en) * | 2019-08-29 | 2023-11-08 | Board of Regents, The University of Texas System | CELL CRYOPRESERVATION MEDIUM |
US20210093669A1 (en) * | 2019-09-26 | 2021-04-01 | Nantbio, Inc. | Primary T-Cell Expansion |
CN110747166B (zh) * | 2019-10-11 | 2021-07-09 | 厦门大学 | 一种外周血t细胞的体外扩增培养方法 |
KR20220105664A (ko) | 2019-11-26 | 2022-07-27 | 노파르티스 아게 | Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도 |
MX2022010685A (es) | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
CN115175695A (zh) * | 2020-02-27 | 2022-10-11 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
MX2022013065A (es) * | 2020-04-22 | 2022-12-08 | Iovance Biotherapeutics Inc | Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente. |
CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
KR20230058427A (ko) | 2020-08-21 | 2023-05-03 | 노파르티스 아게 | Car 발현 세포의 생체내 생성을 위한 조성물 및 방법 |
WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
AU2022330406A1 (en) * | 2021-08-20 | 2024-03-07 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
CN114317435B (zh) * | 2021-12-30 | 2024-02-27 | 杭州芯递力生物科技有限公司 | 一种获得抗原特异性t细胞的方法 |
WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
AU726198B2 (en) * | 1996-03-04 | 2000-11-02 | Targeted Genetics Corporation | Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes |
FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
ATE373078T1 (de) * | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
GB0224442D0 (en) * | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
JP2006524991A (ja) * | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的t細胞の作製および単離の方法 |
AU2005250408B2 (en) * | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
EP1888758A2 (en) | 2005-05-20 | 2008-02-20 | VIRxSYS Corporation | Transduction of primary cells |
JP5666903B2 (ja) * | 2007-05-23 | 2015-02-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 導入遺伝子の発現を増強するための方法および組成物 |
SI2496698T1 (sl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
JP5947311B2 (ja) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変t細胞の使用 |
CN103502439B (zh) * | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
CA2869562C (en) * | 2012-04-11 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
KR102141259B1 (ko) * | 2012-09-04 | 2020-08-05 | 셀렉티스 | 멀티―체인 키메라 항원 수용체 및 그것의 용도들 |
EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
WO2014055442A2 (en) * | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
-
2015
- 2015-04-24 CA CA2946552A patent/CA2946552A1/en active Pending
- 2015-04-24 KR KR1020167032997A patent/KR20160141865A/ko active Search and Examination
- 2015-04-24 RS RS20200744A patent/RS60544B1/sr unknown
- 2015-04-24 ES ES15783117T patent/ES2800906T3/es active Active
- 2015-04-24 SI SI201531225T patent/SI3134095T1/sl unknown
- 2015-04-24 PL PL15783117T patent/PL3134095T3/pl unknown
- 2015-04-24 US US15/306,729 patent/US20170051252A1/en active Pending
- 2015-04-24 LT LTEP15783117.3T patent/LT3134095T/lt unknown
- 2015-04-24 AU AU2015249376A patent/AU2015249376C1/en active Active
- 2015-04-24 EP EP20170239.6A patent/EP3738597A1/en active Pending
- 2015-04-24 BR BR112016024957A patent/BR112016024957A2/pt active Search and Examination
- 2015-04-24 CN CN201580033084.1A patent/CN106456670B/zh active Active
- 2015-04-24 JP JP2016564075A patent/JP6817069B2/ja active Active
- 2015-04-24 SG SG11201608744VA patent/SG11201608744VA/en unknown
- 2015-04-24 DK DK15783117.3T patent/DK3134095T3/da active
- 2015-04-24 KR KR1020187026618A patent/KR101988614B1/ko active IP Right Grant
- 2015-04-24 KR KR1020197016321A patent/KR102161927B1/ko active IP Right Grant
- 2015-04-24 CN CN201911200096.5A patent/CN110819595A/zh active Pending
- 2015-04-24 PT PT157831173T patent/PT3134095T/pt unknown
- 2015-04-24 SG SG10201808258SA patent/SG10201808258SA/en unknown
- 2015-04-24 HU HUE15783117A patent/HUE049514T2/hu unknown
- 2015-04-24 WO PCT/US2015/027518 patent/WO2015164745A1/en active Application Filing
- 2015-04-24 NZ NZ725201A patent/NZ725201A/en unknown
- 2015-04-24 RU RU2016145968A patent/RU2741899C2/ru active
- 2015-04-24 MX MX2016013963A patent/MX370018B/es active IP Right Grant
- 2015-04-24 EP EP15783117.3A patent/EP3134095B1/en active Active
-
2016
- 2016-10-13 IL IL248349A patent/IL248349B/en active IP Right Grant
- 2016-10-18 ZA ZA2016/07175A patent/ZA201607175B/en unknown
- 2016-10-24 MX MX2019014009A patent/MX2019014009A/es unknown
-
2018
- 2018-03-08 JP JP2018041688A patent/JP2018087254A/ja not_active Withdrawn
- 2018-05-25 AU AU2018203687A patent/AU2018203687C1/en active Active
-
2019
- 2019-04-11 ZA ZA2019/02286A patent/ZA201902286B/en unknown
- 2019-11-01 JP JP2019199637A patent/JP7012056B2/ja active Active
-
2020
- 2020-06-19 HR HRP20200978TT patent/HRP20200978T1/hr unknown
- 2020-07-20 CY CY20201100663T patent/CY1123142T1/el unknown
- 2020-08-09 IL IL276593A patent/IL276593B/en unknown
-
2022
- 2022-01-18 JP JP2022005510A patent/JP2022040287A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2810092C2 (ru) * | 2018-09-27 | 2023-12-21 | Отолус Лимитед | Химерный антигенный рецептор |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016145968A (ru) | Улучшенные способы производства средств адоптивной клеточной терапии | |
HRP20210116T1 (hr) | Poboljšane kompozicije t stanica | |
Kagoya et al. | Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy | |
JP6992117B2 (ja) | キメラ抗原受容体 | |
Inozume et al. | Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase | |
JP2022040287A5 (ru) | ||
JP2020058380A (ja) | キメラ抗原受容体及びその製造方法 | |
JP2021505131A5 (ru) | ||
EP3575325A1 (en) | Multi-target chimeric antigen receptor | |
RU2018134771A (ru) | Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение | |
JP2020506700A5 (ru) | ||
JP2019525956A5 (ru) | ||
KR20180012754A (ko) | 변형된 감마 델타 t 세포 및 이의 용도 | |
JP2018514204A5 (ru) | ||
JP2017518052A5 (ru) | ||
RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
EP2964753A1 (en) | Targeting cd138 in cancer | |
CN105473731A (zh) | 自身癌抗原特异性cd8+t细胞的分离及增殖方法 | |
DK3029137T3 (en) | GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF | |
KR20210018838A (ko) | 유전자 조작된 세포 및 응용 | |
JP2023527194A (ja) | 腫瘍微小環境を逆転させる融合タンパク質及びその使用 | |
CN112771167A (zh) | 表达有趋化因子的细胞及用途 | |
KR20210111244A (ko) | 태반-유래 동종이계 car-t 세포 및 이의 용도 | |
US20220280564A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20211118 |